康弘药业(002773.SZ)：依帕司他片取得药品注册证书

Group 1 - The core point of the article is that Kanghong Pharmaceutical has received the drug registration certificate for Ipatasertib from the National Medical Products Administration, indicating regulatory approval for the drug [1] - The approved indication for Ipatasertib is diabetic neuropathy, which highlights the company's focus on addressing complications related to diabetes [1]